Celltrion Collaborates with Inhalon to Develop Regdanvimab (CT-P59) for the Treatment of COVID-19 at Home
Shots:
- The companies collaborate to develop IN-006 (an inhaled form of regdanvimab) to treat patients with COVID-19. The results are expected in 2022
- Inhalon will start a P-I study of nebulized regdanvimab in the next few mos. & plans to complete at the end of 2021 while the study is funded by $7M from the US AMRDC. Celltrion has completed a P-III study which demonstrates that regdanvimab reduced the risk of hospitalization or death by 72% for patients with COVID-19 & 70% for all patients
- Additionally- in vitro & in vivo pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD & neutralizes wild type & mutant variants of concern including Alpha variant
| Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Tags
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
